TRAW
Traws Pharma·NASDAQ
--
--(--)
--
--(--)
TRAW fundamentals
Traws Pharma (TRAW) released its earnings on Aug 14, 2025: revenue was 2.73M (YoY +4694.74%), beat estimates; EPS was -0.11 (YoY +99.91%), beat estimates.
Revenue / YoY
2.73M
+4694.74%
EPS / YoY
-0.11
+99.91%
Report date
Aug 14, 2025
TRAW Earnings Call Summary for Q2,2025
- Clinical Trial Progress: Phase II COVID studies expected to report by year-end 2025; bird flu trial deferred but ready for quick启动.
- Financial Highlights: Reduced expenses (R&D -42.5%, G&A -15% YoY), net loss of $0.9M due to one-time charge.
- Market Potential: $1.5B for COVID drug in underserved patients; bird flu preparedness with BARDA discussions.
EPS
Actual | -11.25 | -15 | -11.25 | -15 | -7.5 | -6.75 | -5.5 | -4.25 | -5 | -4.75 | -6.5 | -6.5 | -7 | -5 | -5.75 | -4.75 | -6 | -121.75 | -8.81 | 101.35 | 2.09 | -0.11 | ||||||||||
Forecast | -20.625 | -11.25 | -12.5 | -12.5 | -11.25 | -7.125 | -8.1667 | -6.75 | -4.6875 | -4.9375 | -5.3125 | -6.9375 | -7.4375 | -7.8125 | -7.25 | -6.3333 | -5.875 | -6.25 | -6.25 | -9.55 | -8.04 | -8.75 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +45.45% | -33.33% | +10.00% | -20.00% | +33.33% | +5.26% | +32.65% | +37.04% | -6.67% | +3.80% | -22.35% | +6.31% | +5.88% | +36.00% | +20.69% | +25.00% | -2.13% | -1848.00% | -40.96% | +1161.26% | +126.00% | +98.74% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 52.00K | 56.00K | 66.00K | 51.00K | 56.00K | 57.00K | 57.00K | 56.00K | 56.00K | 57.00K | 57.00K | 46.00K | 56.00K | 57.00K | 57.00K | 56.00K | 56.00K | 57.00K | 57.00K | 56.00K | 57.00K | 2.73M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 88.00K | 173.00K | 1.39M | 45.00K | 60.00K | 20.00K | 53.33K | 59.50K | 79.00K | 73.00K | 73.67K | 80.00K | 79.00K | 69.25K | 69.25K | 65.33K | 60.00K | 60.00K | 60.00K | 60.00K | 60.00K | 60.00K |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40.91% | -67.63% | -95.26% | +13.33% | -6.67% | +185.00% | +6.88% | -5.88% | -29.11% | -21.92% | -22.62% | -42.50% | -29.11% | -17.69% | -17.69% | -14.29% | -6.67% | -5.00% | -5.00% | -6.67% | -5.00% | +4455.00% |
Earnings Call
You can ask Aime
Did Traws Pharma beat or miss consensus estimates last quarter?What factors drove the changes in Traws Pharma's revenue and profit?What is the market's earnings forecast for Traws Pharma next quarter?What were the key takeaways from Traws Pharma’s earnings call?What does Traws Pharma do and what are its main business segments?What is Traws Pharma's latest dividend and current dividend yield?What is Traws Pharma's gross profit margin?What were the key takeaways from Traws Pharma's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
